TUB Stock Analysis: Tubize-Fin | BR
Biotechnology | BR, Belgium | Market Cap: 8.030m EUR | 12M Return: -7.5% | BE0003823409 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.84M
Warnings
Tailwinds
Seasonality
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 5.12 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.05 > 3% & CFO 98.4m > Net Income 98.4m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.5m) vs 12m ago 0.0% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.00%; Δ -0.00% > 0%) |
| Interest Coverage Ratio: 94.37 > 6 (EBIT TTM 99.5m / Interest Expense TTM 1.05m) |
| A: 0.00 (Total Current Assets 49.9m - Total Current Liabilities 48.6m) / Total Assets 1.99b |
| B: 0.14 (Retained Earnings 281.0m / Total Assets 1.99b) |
| C: 0.05 (EBIT TTM 99.5m / Avg Total Assets 1.96b) |
| D: 5.51k (Book Value of Equity 1.99b / Total Liabilities 360k) |
| Altman-Z'' = 5.79k = AAA |
As of October 23, 2026, the stock is trading at EUR 209.20 with a total of 141,154 shares traded. Over the past week, the price has changed by +20.16%, over one month by +15.96%, over three months by -0.38% and over the past year by -7.50%.
Current recommended Stop Loss: 203.10 (which is 2.9% or 1.3 ATR below the current price).
Tubize-Fin has no consensus analysts rating.
P/E Trailing = 79.4714
P/E Forward = 30.9598
P/S = 999999.9999
P/B = 3.9934
P/EG = 1.2394
Revenue TTM = 0.0 EUR
EBIT TTM = 99.5m EUR
EBITDA TTM = 99.5m EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 7.98b EUR (8.03b + (null Debt) - CCE 49.9m)
Interest Coverage Ratio = 94.37 (Ebit TTM 99.5m / Interest Expense TTM 1.05m)
EV/FCF = 81.13x (Enterprise Value 7.98b / FCF TTM 98.4m)
FCF Yield = 1.23% (FCF TTM 98.4m / Enterprise Value 7.98b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.29k) / Revenue TTM)
Tobins Q-Ratio = 4.02 (Enterprise Value 7.98b / Total Assets 1.99b)
Interest Expense / Debt = unknown (Interest Expense 1.05m / Debt none)
Taxrate = 0.0% (0.0 / 93.2m)
NOPAT = 99.5m (EBIT 99.5m * (1 - 0.00%))
Current Ratio = 1.03 (Total Current Assets 49.9m / Total Current Liabilities 48.6m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 99.5m)
Debt / FCF = unknown (Net Debt none / FCF TTM 98.4m)
Total Stockholder Equity = 1.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.02% (Net Income 98.4m / Total Assets 1.99b)
RoE = 5.15% (Net Income TTM 98.4m / Total Stockholder Equity 1.91b)
RoCE = 5.13% (EBIT 99.5m / Capital Employed (Total Assets 1.99b - Current Liab 48.6m))
RoIC = 5.01% (NOPAT 99.5m / Invested Capital 1.99b)
WACC = 6.64% (E(8.03b)/V(8.03b) * Re(6.64%) + (debt-free company))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 75.44% ; FCFF base≈98.4m ; Y1≈98.8m ; Y5≈104.6m
[DCF] Fair Price = 36.56 (EV 1.63b - Net Debt 0.0 = Equity 1.63b / Shares 44.5m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0